BenevolentAI
broad portfolio and high quality peer reviewed publications we protect both our drug pipeline and our technology platform using patents copyright and trade secrets we use rights to retain our competitive advantages and where appropriate publish our and technology research in order to improve the lives of patients and retain leadership in the eld as potential treatment for acute respiratory disease a novel antiviral mechanism from public data using knowledge graph and tools in just hours most effective treatment for covid shown in comprehensive tech and drug patent portfolios preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs time slicing experiment showing we can predict future therapeutic targets and clinical trial successes beyond other state of the art approaches learning structural comparison of protein binding sites convolutional neural network designed to structurally compare protein binding sites to help guide hit and characterization of protein function drug patent applications across programmes tech patent applications covering all four key tech areas peer reviewed papers published | BenevolentAI
Company
Deck Type
Deck date
December 2021
Slide
18 of 42
Related slides by other companies
SPAC
March 2021
Mergers and Acquisitions
October 2022
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io